Verismo Therapeutics, a clinical-stage CAR T company pioneering the KIR-CAR platform, today provided additional details on ...

Rigel Pharmaceuticals, Inc. , a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced seven upcoming poster presentations at the 2025 American Society of ...

Clinical validation of the Azymetric platform is demonstrated by the accelerated approval our partner Jazz Pharmaceuticals received from the U.S. Food and Drug Administration in 2024 for Ziihera® ...

MAIA Biotechnology, Inc. , a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that an abstract about the efficacy data from the Phase ...

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human disease ...

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres ...

NewBiologix, a next-generation biotechnology company pioneering the future of recombinant adeno-associated virus (rAAV) production through a unique DNA-based platform built on stable cell line ...

About PYRUKYND® (mitapivat) U.S. INDICATION PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.

The 54th International Symposium on High Performance Liquid Phase Separations and Related Techniques (HPLC 2025) will be held ...

2025 Student Symposium Format Students must choose between an oral presentation or a poster presentation ... For both options, students must first submit an abstract for approval by their faculty or ...

Analysis of EFX results with AI-based digital pathology underscores the potential value in evaluating histopathology responseData contribute to growing body of support around the anti-fibrotic ...

Premeds can get an edge by being published several ways, from hypothesis-based research papers to conference abstracts.